Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Therapeutic Area

IL-23

Therapeutic area intelligence for IL-23 with 7 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 7
Catalysts: 0
Companies: 3

Companies

Assets

Lebrikizumab →

Recent signals(7)

RegulatoryJuly 23, 2026

FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma

The FDA has accepted a supplemental biologics application for ILUMYA (tildrakizumab) from Sun Pharma.

Regulatory

July 21, 2026

FDA Accepts Supplement for TREMFYA (Guselkumab) by Janssen Biotech

The FDA has accepted a supplemental application for TREMFYA (guselkumab) from Janssen Biotech.

RegulatoryJuly 3, 2026

FDA Accepts Supplement for SKYRIZI (Risankizumab) by AbbVie

The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.

RegulatoryJune 21, 2026

FDA Accepts Supplement for Lebrikizumab by Eli Lilly

The FDA has accepted the supplemental biologics application for Lebrikizumab (BLA761306) from Eli Lilly.

ClinicalJune 21, 2026

Eli Lilly's Remternetug Study in Healthy Chinese Participants Initiated

Eli Lilly is conducting a safety and tolerability study of remternetug in healthy Chinese participants, lasting up to 25 weeks.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab)

The FDA has accepted a supplemental application for SKYRIZI, indicating ongoing development and potential label expansion.

RegulatoryJune 18, 2026

FDA Accepts Supplement Application for SKYRIZI (Risankizumab) by AbbVie

The FDA has accepted a supplemental application for SKYRIZI (Risankizumab) from AbbVie.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.